Research analysts covering E2XA34.
Recent press releases and 8-K filings for E2XA34.
Exact Sciences Reports Strong Q3 Growth, Outlines Profitability Path, and Details New Product Strategies
E2XA34
Revenue Acceleration/Inflection
Guidance Update
Product Launch
- Exact Sciences reported 20% total company growth in Q3, with screening accelerating to 22%, marking its highest growth rate in over two years, and generated more than triple the free cash through three quarters compared to all of last year.
- The company anticipates nearly 50% profit growth in 2025 and aims for 20%+ EBITDA margins by 2027, supported by a cost-out program targeting $50 million this year and $150 million next year.
- Cologuard Plus has secured positive coverage decisions from four of the top 10 commercial payers and expects to have all ten on board, with a 16% price increase.
- Exact Sciences plans to launch a CRC blood test by mid-2025 and is observing positive early adoption for its multi-cancer early detection (MCED) test, CancerGuard, priced at $689.
Nov 18, 2025, 12:30 PM
Exact Sciences Highlights Strong Growth, Cologuard Plus Adoption, and New Product Pipeline
E2XA34
Revenue Acceleration/Inflection
Product Launch
Guidance Update
- Exact Sciences reported 20% total company growth in Q3, with screening accelerating to 22%, marking its highest growth rate in over two years. The company anticipates nearly 50% profit growth for the second consecutive year in 2025 and is on track for 20%+ EBITDA margins by 2027, supported by a cost-out program of $50 million this year and $150 million next year.
- Cologuard Plus has secured positive coverage decisions from 10 out of 10 top commercial payers, representing over 60% of US lives, with contracting discussions ongoing. The company expects to phase out Cologuard and transition to Cologuard Plus next year, which includes a 16% price increase—the first in 11 years.
- The company is expanding its portfolio with several new tests, including a CRC blood test expected mid-next year targeting 5-10% of the market , the MRD test Oncodetect which recently received Medicare coverage , and the multi-cancer screening test CancerGuard, launched at an FSA-eligible price of $689. Global expansion for CancerGuard is planned.
- Exact Sciences emphasizes its recurring revenue model, with 2 million rescreen opportunities this year and a 90% return rate for third Cologuard test kits. CareGap testing contributed mid-single digits to top-line growth in the back half of the year, exceeding $125 million last year.
Nov 18, 2025, 12:30 PM
Exact Sciences Reports Strong Commercial Execution and Growth, Outlines Future Product Launches
E2XA34
Revenue Acceleration/Inflection
Guidance Update
Product Launch
- Exact Sciences demonstrated strong commercial execution, achieving 20% total company growth in Q3, with screening accelerating to 22%, and the precision oncology business growing 12%.
- The company anticipates nearly 50% profit growth in 2025, supported by a cost-out program targeting $50 million this year and $150 million next year, with a long-term goal of 20%+ EBITDA margins by 2027.
- Cologuard Plus has secured positive coverage decisions from 10 out of 10 top payers, covering over 60% of U.S. lives, and is expected to phase out Cologuard with a 16% price increase.
- New product launches include a CRC blood test expected by mid-next year and the multi-cancer screening test, CancerGuard, priced at $689, which has shown promising results in its first 45 days.
- The company has expanded its EMR connectivity to its 500th large health system, leading to an immediate 30% increase in order rates, enhancing its ability to launch new tests.
Nov 18, 2025, 12:30 PM
Healthcare Symposium Highlights Multi-Cancer Early Detection Innovations and Economic Impact
E2XA34
Product Launch
New Projects/Investments
- The 7th Annual Gabelli Funds Columbia Business School Healthcare Symposium focused on multi-cancer early detection (MCED), featuring discussions from leaders at Quest Diagnostics, Exact Sciences, Guardant Health, and Grail.
- Guardant Health's Shield colorectal screening product is a successful launch, and the company is expanding its focus to lung cancer and building real-world evidence for multi-cancer screening.
- Exact Sciences is leveraging its established Cologuard brand, which has screened over 20 million people, to introduce its Cancerguard test for multi-cancer early detection, positioning it as complementary to standard screenings.
- Panelists presented data indicating that MCED could reduce stage four cancer incidence by over 40% and overall cancer mortality by 18% over a 10-year period, while being four to seven times less expensive than detecting late-stage cancer.
- Industry efforts include advocating for a multi-cancer early detection bill in Congress to enable Medicare reimbursement, with Quest Diagnostics utilizing its vast network, including 8,000 phlebotomist centers, to support access and evidence generation for these innovative tests.
Nov 14, 2025, 1:50 PM
Healthcare Symposium Highlights Multi-Cancer Early Detection Advancements
E2XA34
New Projects/Investments
Product Launch
- The 7th Annual Gabelli Funds Columbia Business School Healthcare Symposium focused on multi-cancer early detection (MCED), featuring discussions from Exact Sciences, Guardant Health, Grail, and Quest Diagnostics.
- Companies emphasized MCED's role as complementary to existing cancer screenings, aiming to improve early detection for various cancer types, including pancreatic cancer.
- Quest Diagnostics serves as a critical partner, leveraging its extensive network to provide broad access to MCED innovations and is also developing its own multi-cancer risk test with MD Anderson.
- Early cancer detection through MCED is projected to significantly reduce stage four cancer incidence by over 40% and overall cancer mortality by 18%, leading to substantial healthcare cost savings.
- Industry participants are actively advocating for legislation to enable Medicare reimbursement for MCED tests, recognizing the need for robust evidence to demonstrate clinical utility and cost-effectiveness to payers.
Nov 14, 2025, 1:50 PM
Exact Sciences Reports Q3 2025 Results with Revenue and Adjusted EBITDA Growth, Raises Full-Year Guidance
E2XA34
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Exact Sciences reported total revenue of $850.7 million in Q3 2025, marking a 20% increase year-over-year.
- Adjusted EBITDA for Q3 2025 reached $135.4 million, an increase of 37% year-over-year, with an adjusted EBITDA margin of 16%.
- The company reported a GAAP net loss of $(19.6) million, or $(0.10) per share, in Q3 2025, an improvement from a net loss of $(38.2) million, or $(0.21) per share, in Q3 2024.
- Free cash flow for the nine months ended September 30, 2025, was $236.3 million.
- Exact Sciences updated its 2025 guidance, raising the outlook for total revenue to a range of $3.220 – 3.235 billion and adjusted EBITDA to $470 – 480 million.
Nov 3, 2025, 10:00 PM
Exact Sciences Announces Record Q3 2025 Results and Raises Full-Year Guidance
E2XA34
Earnings
Guidance Update
Product Launch
- Exact Sciences reported record Q3 2025 revenue of $851 million, a 20% increase year-over-year, with screening revenue growing 22% to $666 million and precision oncology revenue growing 12% to $183 million.
- The company raised its full-year 2025 guidance, projecting total revenue between $3.22 billion and $3.235 billion and adjusted EBITDA between $470 million and $480 million.
- Q3 2025 adjusted EBITDA increased 37% year-over-year to $135 million, with margins expanding 200 basis points to 16%, and free cash flow reached $190 million for the quarter.
- Exact Sciences launched CancerGuard, a multi-cancer early detection test, and expanded access to Cologuard Plus, securing positive coverage decisions from all top 10 payers and signing contracts with Aetna and Highmark.
- The company saw a record number of active ordering providers for Cologuard, climbing to over 200,000, and is on track to deliver $150 million in savings by 2026 through its productivity program.
Nov 3, 2025, 10:00 PM
Exact Sciences Reports Record Q3 2025 Results and Raises Full-Year Guidance
E2XA34
Earnings
Guidance Update
Product Launch
- Exact Sciences reported record Q3 2025 revenue of $851 million, a 20% year-over-year increase, and adjusted EBITDA of $135 million, up 37% year-over-year, with margins expanding 200 basis points to 16%. The company also raised its full-year 2025 revenue guidance to between $3.22 billion-$3.235 billion and adjusted EBITDA guidance to between $470 million-$480 million.
- The company launched CancerGuard, its multi-cancer early detection test, in Q3 2025.
- Cologuard Plus has received positive coverage decisions from all top 10 payers, with contracts signed with Aetna and Highmark, and the company plans to sunset the original Cologuard test next year.
- Exact Sciences experienced a record quarter in its care gap business, which is contributing to accelerated growth.
Nov 3, 2025, 10:00 PM
Exact Sciences Reports Record Q3 2025 Results and Raises Full-Year Guidance
E2XA34
Earnings
Guidance Update
Product Launch
- Exact Sciences reported record Q3 2025 revenue of $851 million, a 20% year-over-year increase, driven by 22% growth in screening revenue to $666 million and 12% growth in precision oncology revenue to $183 million.
- Adjusted EBITDA for Q3 2025 was $135 million, an increase of 37% year-over-year, with margins expanding 200 basis points to 16%.
- The company raised its full-year 2025 revenue guidance to between $3.22 billion and $3.235 billion and adjusted EBITDA guidance to between $470 million and $480 million.
- Key developments include the launch of CancerGuard, a multi-cancer early detection test, and continued expansion of Cologuard Plus access, including contracts with Aetna and Highmark.
- Exact Sciences generated $190 million in free cash flow during Q3 2025, contributing to a year-to-date total of $236 million, an increase of 270% year-over-year.
Nov 3, 2025, 10:00 PM
Exact Sciences Reports Q4 and Full-Year 2024 Results, Issues 2025 Guidance, and Announces Three New Test Launches
E2XA34
Earnings
Guidance Update
Product Launch
- Exact Sciences reported Q4 2024 revenue growth of 10% (or 11% on a core basis) and a 52% increase in Adjusted EBITDA to $75 million.
- For the full year 2024, core revenue grew 11% to $2.75 billion, Adjusted EBITDA increased 48%, and free cash flow more than doubled. The company ended the year with $1.04 billion in cash and securities.
- The company provided 2025 full-year revenue guidance between $3.025 billion and $3.085 billion, implying 11% total revenue growth at the midpoint, and Adjusted EBITDA between $410 million and $440 million.
- Exact Sciences plans to launch three new tests in 2025: Cologuard Plus, OncoDetect (molecular residual disease), and CancerGuard (multi-cancer screening).
- Cologuard Plus, with 95% sensitivity and 94% specificity, secured FDA approval and Medicare pricing of $592, and is expected to contribute approximately two points of lift to 2025 screening revenue, primarily in the second half.
Feb 19, 2025, 10:00 PM
Quarterly earnings call transcripts for E2XA34.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more